BCL2 and B-cell chronic lymphocytic leukemia: Indefinite treatment paradigms, as the ones represented by ibrutinib itself and by the single-agent BCL2-inhibitor venetoclax [26], are nowadays challenged by fixed term combinations at CLL relapse and by minimal residual disease-driven definite term strategies in the next future [27,28].